<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2206">
  <stage>Registered</stage>
  <submitdate>12/12/2008</submitdate>
  <approvaldate>12/12/2008</approvaldate>
  <nctid>NCT00808028</nctid>
  <trial_identification>
    <studytitle>A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents</studytitle>
    <scientifictitle>A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>B1971005</secondaryid>
    <secondaryid>6108A1-2001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Meningitis, Meningococcal</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - meningococcal B rLP2086 vaccine.
Other interventions - meningococcal B rLP2086 vaccine.
Other interventions - meningococcal B rLP2086 vaccine.
Other interventions - normal saline (placebo)

Experimental: 1 - dose level 1 rLP2086 vaccine

Experimental: 2 - dose level 2 rLP2086 vaccine

Experimental: 3 - dose level 3 rLP2086 vaccine

Placebo Comparator: 4 - normal saline (placebo)


Other interventions: meningococcal B rLP2086 vaccine.
vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

Other interventions: meningococcal B rLP2086 vaccine.
vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

Other interventions: meningococcal B rLP2086 vaccine.
vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

Other interventions: normal saline (placebo)
vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With at Least 4-fold Rise in Recombinant Lipoprotein 2086 (rLP2086) Specific Serum Bactericidal Assay Using Human Complement (hSBA) Titer: Before Vaccination 1 up to 1 Month After Vaccination 2</outcome>
      <timepoint>Before vaccination 1 up to 1 month after vaccination 2</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With at Least 4-fold Rise in Recombinant Lipoprotein 2086 (rLP2086) Specific Serum Bactericidal Assay Using Human Complement (hSBA) Titer: Before Vaccination 1 up to 1 Month After Vaccination 3</outcome>
      <timepoint>Before vaccination 1 up to 1 month after vaccination 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With Atleast One Adverse Event (AE): Stage 1</outcome>
      <timepoint>Vaccination 1 upto 1 Month after vaccination 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With Atleast One Adverse Event (AE): Stage 2</outcome>
      <timepoint>6 month after vaccination 3 up to 48 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (&gt;=) Prespecified Titer Level</outcome>
      <timepoint>1 month before vaccination 1, 1 month after vaccination 2, 3</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male or female subjects between the ages of &gt;=11 and &lt;=18 years at the time of
             enrollment.

          -  Negative urine pregnancy test for all female subjects.

          -  Parent/legal guardian or subject under supervision of the parent/legal guardian must
             be able to complete all relevant study procedures during study participation.</inclusivecriteria>
    <inclusiveminage>11</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of any invasive meningococcal disease.

          -  A previous anaphylactic or severe vaccine-associated adverse reaction.

          -  Any clinically significant chronic disease.

          -  A known or suspected disease of the immune system or those receiving immunosuppressive
             therapy, including systemic corticosteroids. Topical, inhaled or intra-articular
             corticosteroids are allowed.

          -  Participation in another investigational study in the 1-month (30-day) period before
             study visit 1 and during the conduct of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>538</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Queensland Paediatric Infectious Diseases (QPID) Laboratory - Herston</hospital>
    <hospital>Department of Paediatrics, Women's &amp; Children's Hospital - North Adelaide</hospital>
    <hospital>Royal Children's Hospital - Carlton</hospital>
    <hospital>Children's Clinical Research Facility, Vaccine Trials Group (VTG), - Subiaco</hospital>
    <postcode>4029 - Herston</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3053 - Carlton</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Debica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Leczna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lubartow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Melno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Oborniki Slaskie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Siemianowice Slaskie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Torun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Trzebnica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pontevedra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Almeria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and immunogenicity of an investigational
      meningococcal B rLP2086 vaccine in adolescents aged 11 to 18 years old.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00808028</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>